NCT02358161View on ClinicalTrials.gov

Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

January 31, 2019

Conditions
Pancreatic Cancer
Interventions
DRUG

gemcitabine and nab paclitaxel

DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer

Trial Locations (1)

1105 AZ

Academic Medical Center, Amsterdam

Sponsors
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER